Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro synthesis of enzymatically active HIV-1 protease for rapid phenotypic resistance profiling.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 1 Apr 2005

Hoffmann Dieter, Buchberger Bernd, Nemetz Cordula

Abstract excerpt

BACKGROUND: Given the expanding antiretroviral therapy, inexpensive and fast HIV drug resistance assays are urgently needed. In this view, we have developed a novel phenotypic resistance test for HIV-1 protease inhibitors (PIs) based on recombinant expression of patient-derived HIV PR in Escherichia coli and subsequent enzymatic testing in a fluorescent readout. OBJECTIVES: To facilitate and expedite the test...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cloning, Molecular
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Nucleic Acid Amplification Techniques

Share to Protein Biosynthesis

Share to Transcription, Genetic

Source

Identifiers

PMID: 15780808
DOI: 10.1016/j.jcv.2004.09.016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro synthesis of enzymatically active HIV-1 protease for rapid phenotypic resistance profiling.PMID 15780808Read ↗

Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors.Semantic proximity Read ↗

Rapid enzymatic test for phenotypic HIV protease drug resistance.Semantic proximity Read ↗

Quantitative evaluation of the recombinant HIV-1 phenotype to protease inhibitors by a single-step strategy.Semantic proximity Read ↗

Development and evaluation of a phenotypic assay monitoring resistance formation to protease inhibitors in HIV-1-infected patients.Semantic proximity Read ↗

Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation.Semantic proximity Read ↗

Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants.Semantic proximity Read ↗

A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.Semantic proximity Read ↗

Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors.Semantic proximity Read ↗

A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.Semantic proximity Read ↗

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.Semantic proximity Read ↗

A synthetic HIV-1 subtype C backbone generates comparable PR and RT resistance profiles to a subtype B backbone in a recombinant virus assay.Semantic proximity Read ↗

Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.